Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Plus Dexamethasone in Newly Diagnosed ITP
NCT05932524Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Durable response at 6 months. Status: unknown.
02
Drugs
baricitinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05932524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932524.